1. Search Result
Search Result
Results for "

CETP

" in MedChemExpress (MCE) Product Catalog:

28

Inhibitors & Agonists

4

Natural
Products

2

Antibodies

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13327
    Evacetrapib
    3 Publications Verification

    LY2484595

    CETP Cardiovascular Disease
    Evacetrapib is a potent and selective of CETP inhibitor, which inhibits human recombinant CETP protein (IC50 5.5 nM) and CETP activity in human plasma (IC50 36 nM) in vitro.
    Evacetrapib
  • HY-18778

    TA-8995; DEZ-001; AMG-899

    CETP Apolipoprotein LPL Receptor LDLR Cardiovascular Disease
    Obicetrapib (TA-8995; DEZ-001) is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) .
    Obicetrapib
  • HY-12090
    Anacetrapib
    3 Publications Verification

    MK-0859

    PCSK9 Cardiovascular Disease
    Anacetrapib is a potent CETP inhibitor, with IC50s of 7.9±2.5 nM and 11.8±1.9 nM for rhCETP and C13S CETP mutant, respectively.
    Anacetrapib
  • HY-12089

    CP-529414

    CETP Endocrinology
    Torcetrapib (CP-529414) is a selective, potent cholesteryl ester transfer protein (CETP) inhibitor. A typical inhibition curve for whole human plasma, having a CETP concentration of 37 nM .
    Torcetrapib
  • HY-14950
    Dalcetrapib
    2 Publications Verification

    JTT-705; RO4607381

    CETP Cardiovascular Disease Cancer
    Dalcetrapib (JTT-705) is an orally active cholesteryl ester transfer protein (CETP) inhibitor with IC50s of 204.6 nM and 6 μM against recombinant human (rh) CETP and human plasma CETP, respectively .
    Dalcetrapib
  • HY-W414588

    HMG-CoA Reductase (HMGCR) CETP Metabolic Disease
    Colestolone is a 15-ketosterol compound and an orally active inhibitor of HMG-CoA reductase. Colestolone can inhibit the activity of cholesteryl ester transfer protein (CETP) in vitro (IC50 = 660 μM). Colestolone is a cholesterol-lowering agent, and can be used in the research of endocrine and metabolic diseases such as hyperlipidemia .
    Colestolone
  • HY-116078

    CETP Cardiovascular Disease
    CKD-519 is a selective and potent cholesteryl ester transfer protein (CETP) inhibitor, which inhibits CETP-mediated transfer of cholesteryl ester in human serum with an IC50 of 2.3 nM .
    CKD-519
  • HY-W015752

    Drug Intermediate Others
    5-Methoxyresorcinol is a model molecule of the A ring of flavonoids, specifically simulating the chemical behavior of the resorcinol-type A ring found in catechins. 5-Methoxyresorcinol exhibits extremely low reactivity of tocopherol. 5-Methoxyresorcinol hardly inhibits cholesteryl ester transfer protein (CETP) .
    5-Methoxyresorcinol
  • HY-171883

    Cannabinoid Receptor CETP MHC Metabolic Disease Inflammation/Immunology Cancer
    BI-5756 is a CETP inhibitor and cannabinoid receptor 1 (CB1) agonist. BI-5756 can significantly increase HDL-C levels and reduce LDL-C levels. BI-5756 can also enhance the function of regulatory T cells while maintaining T cell-mediated anti-tumor activity. BI-5756 can directly inhibit the growth of tumor cells and upregulate the expression of MHC I, MHC II, and CD80 on tumor cells. BI-5756 has a protective effect in graft-versus-host disease models. BI-5756 can be used in research on tumors, graft-versus-host disease, and metabolic diseases .
    BI-5756
  • HY-19614

    CETP Cardiovascular Disease
    BMS-795311 is a potent and orally bioavailable inhibitor of cholesteryl ester transfer protein (CETP), with IC50s of 4 nM in an enzyme-based scintillation proximity assay (SPA) and 0.22 μM in a human whole plasma assay (hWPA), respectively .
    BMS-795311
  • HY-107997

    CETP Cardiovascular Disease
    TAP311 is a cholesteryl ester transfer protein (CETP) inhibitor with an IC50 of 62 nM .
    TAP311
  • HY-123039

    CETP Metabolic Disease
    CP-532623 is a CETP inhibitor and elevates high-density lipoprotein cholesterolion. CP-532623 is a close structural analogue of Torcetrapib. CP-532623 has highly lipophilic properties .
    CP-532623
  • HY-105316

    CETP Metabolic Disease
    CP-800569 is an orally active cholesteryl ester transfer protein (CETP) inhibitor. CP-800569 can decrease low-density lipoprotein and postprandial triglyceride and increase high-density lipoprotein. CP-800569 can be used for the research of metabolic disease .
    CP-800569
  • HY-142643

    CETP Metabolic Disease
    CETP-IN-4 is a cholesteryl ester transfer protein (CETP) inhibitor.
    CETP-IN-4
  • HY-128338

    CETP Cardiovascular Disease
    CETP-IN-3 (Compound 13) is an small molecule inhibitor of the plasma glycoprotein cholesterol ester transfer protein (CETP), elevating HDL-C through inhibition of CETP. CETP-IN-3 for the CETP inhibitory activity in the scintillation proximity (SPA) and whole plasma assay (WPA) with IC50s of 0.002 μM and 0.06 μM, respectively .
    CETP-IN-3
  • HY-107054

    ETC-1001

    PPAR Cardiovascular Disease
    ESP-31015 (ETC-1001) is an orally active and non-fibrate based PPARα agonists. ESP-31015 demonstrates significant lipid-regulating effects in the obese Zucker rat model. ESP-31015 can be used in cardiovascular disease research .
    ESP-31015
  • HY-RS02549

    Small Interfering RNA (siRNA) Others

    CETP Human Pre-designed siRNA Set A contains three designed siRNAs for CETP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CETP Human Pre-designed siRNA Set A
    CETP Human Pre-designed siRNA Set A
  • HY-13327R

    LY2484595 (Standard)

    CETP Reference Standards Cardiovascular Disease
    Evacetrapib (Standard) is the analytical standard of Evacetrapib. This product is intended for research and analytical applications. Evacetrapib is a potent and selective of CETP inhibitor, which inhibits human recombinant CETP protein (IC50 5.5 nM) and CETP activity in human plasma (IC50 36 nM) in vitro.
    Evacetrapib (Standard)
  • HY-14950R

    JTT-705 (Standard); RO4607381 (Standard)

    CETP Reference Standards Cardiovascular Disease Cancer
    Dalcetrapib (Standard) is the analytical standard of Dalcetrapib. This product is intended for research and analytical applications. Dalcetrapib (JTT-705) is an orally active cholesteryl ester transfer protein (CETP) inhibitor with IC50s of 204.6 nM and 6 μM against recombinant human (rh) CETP and human plasma CETP, respectively .
    Dalcetrapib (Standard)
  • HY-12090R

    MK-0859 (Standard)

    PCSK9 Reference Standards Cardiovascular Disease
    Anacetrapib (Standard) is the analytical standard of Anacetrapib. This product is intended for research and analytical applications. Anacetrapib is a potent CETP inhibitor, with IC50s of 7.9±2.5 nM and 11.8±1.9 nM for rhCETP and C13S CETP mutant, respectively.
    Anacetrapib (Standard)
  • HY-169723

    CETP Metabolic Disease
    CP 524515 is a potent inhbitor of cholesteryl ester transfer protein (CETP) that leads to elevated high-density lipoprotein cholesterol levels .
    CP 524515
  • HY-123550

    Thrombin CETP Inflammation/Immunology
    Rosenonolactone shows inhibitory activity against prolyl endopeptidase and thrombin and cholesterol ester transfer protein .
    Rosenonolactone
  • HY-132303

    CETP Cardiovascular Disease Metabolic Disease
    MK-8262 is an orally active and potent cholesteryl ester transfer protein (CETP) inhibitor with an IC50 of 53 nM and a log D of 5.3. MK-8262, a bistrifluoromethyl analogue, has the potential for coronary heart disease (CHD) correlated high-density lipoprotein (HDL) and low-density lipoprotein (LDL) research .
    MK-8262
  • HY-W015752R

    Reference Standards Drug Intermediate Others
    5-Methoxyresorcinol (Standard) is an analytical standard for 5-Methoxyresorcinol (HY-W015752). This product is intended for research and analytical applications. 5-Methoxyresorcinol is a model molecule for the A ring of flavonoids, specifically mimicking the chemical behavior of the resorcinol-type A ring in catechins. 5-Methoxyresorcinol exhibits very low tocopherol regeneration activity. 5-Methoxyresorcinol shows little inhibition of cholesteryl ester transfer protein (CETP).
    5-Methoxyresorcinol (Standard)
  • HY-18778B

    TA-8995 potassium; DEZ-001 potassium; AMG-899 potassium

    Apolipoprotein CETP LPL Receptor LDLR Metabolic Disease
    Obicetrapib (TA-8995; DEZ-001) potassium is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib potassium potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib potassium can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) .
    Obicetrapib potassium
  • HY-N8353

    Others Metabolic Disease
    Stachybotramide is a natural fungal metabolite with the property of modulating the activity of cholesteryl ester transfer protein (CETP). Stachybotramide stimulates the transfer of cholesteryl esters (CE) from high-density lipoprotein (HDL) to very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL), increasing the transfer efficiency by 1.3- to 1.5-fold. Stachybotramide slightly reduced the transfer of cholesteryl esters from LDL and VLDL to HDL at 0.5 mM. The effect of Stachybotramide on the transfer of triglycerides (TG) from HDL was not significant. By these results, Stachybotramide was shown to preferentially stimulate the CETP-mediated transfer of cholesteryl esters from HDL to VLDL and LDL .
    Stachybotramide
  • HY-18778A

    TA-8995 sodium; DEZ-001 sodium; AMG-899 sodium

    Apolipoprotein CETP LPL Receptor LDLR Cardiovascular Disease
    Obicetrapib (TA-8995; DEZ-001) sodium is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib sodium potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib sodium can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) .
    Obicetrapib sodium
  • HY-182320

    CETP Cardiovascular Disease
    DRL-17822 is a selective cholesteryl ester transfer protein (CETP) inhibitor. DRL-17822 increases high-density lipoprotein levels. The exposure of DRL-17822 nanocrystal formulation increases significantly after a high-fat breakfast. The exposure of DRL-17822 in the fasted state is higher than that of its nanocrystal formulation. DRL-17822 can be used in the research of type II hyperlipidemia and atherosclerotic cardiovascular disease .
    DRL-17822

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: